Replies to post #3056 on CytoSorbents Corporation (CTSO)

[Walkers dream]

I'm trying to find the technology to which you are referring. Please could you direct us to it.
Thanks.

They have what appears to be a technology already that is equivalent to or better than CTSO's.

[ping_pow_princess]

Fresenius's primary missions are developing equipment and processes that help to reduce the still dramatically high mortality rates of these diseases--acute kidney failure, liver failure, sepsis and multiple organ failure. It should be no surprise that they are financing a research on absorbents for sepsis. This is still in the early stages at the Danube University Krems. The university researchers are researching (gram-negative) sepsis and biocompatibility of adsorbents for blood purification.

CTSO's is the only approved cytokine filter and to quote a favorite poster, Kastlem:

Endotoxin assay for gram negative sepsis was heavily discussed here. For others who may not know: If CytoSorb gets bought by enough hospitals, Spectral's endotoxin assay sales would fail. Endotoxin removal by hemoperfusion is a 'specialist' treatment (endotoxins higher up the cascade), whereas CytoSorb is a genrealist (all cytokines, lower down the cascade) will work no matter whether the organism is gram positive (about 50% are), gram negative (common where the infection source is abdominal), viral or fungal. Generalists survive better than specialists. CytoSorb would be cheaper and applicable to far more cases.

Price tag: Toraymyxin $10,000, Cytosorb, $500